drugset / Trial / NCT03103919

Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management

NCT03103919

Phase 4 Completed 40 enrolled UCB Biopharma S.P.R.L.
RandomizedParallel-groupOpen-labelTreatment

Summary

Evaluate the benefits of Kinesia-360™ wearable technology in addition to standard clinical practice on improving Parkinson´s disease motor symptoms, Neupro dosing regimen and adherence to Neupro compared with only standard clinical practice.

Timeline

Start
2017-03-16
Primary completion
2018-01-02
Completion
2018-01-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Rotigotine Unknown 2 mg
Subject Rotigotine Unknown 4 mg

Indications